Wednesday, February 12, 2025 11:01:14 AM
That quote is already a dated source of information
This is using the most recent information, they include "another year later" from MHRA application (12/2023) and also the convertible financing in 12/2024.
But, still, another year later and the company is still awaiting the outcome of its approval application. Reports suggest that the company is still working closely with consultants on matters related to the review, including preparing for upcoming inspections by the MHRA in the U.S. and the U.K. The company is also reportedly struggling for cash and is currently funding itself through a shoestring effort. In December 2024, it announced a $5 million convertible note financing and standby facility for up to $50 million in additional financing.
How do you feel about your calls for shareholders to buy the support at 60 cents and 50 cents and 40 cents? Will you feel responsible at all if shareholders lose everything here?
Stock is about to reach the value menu level of 4 for a dollar, I'm sure you're proud smh.
This is using the most recent information, they include "another year later" from MHRA application (12/2023) and also the convertible financing in 12/2024.
But, still, another year later and the company is still awaiting the outcome of its approval application. Reports suggest that the company is still working closely with consultants on matters related to the review, including preparing for upcoming inspections by the MHRA in the U.S. and the U.K. The company is also reportedly struggling for cash and is currently funding itself through a shoestring effort. In December 2024, it announced a $5 million convertible note financing and standby facility for up to $50 million in additional financing.
How do you feel about your calls for shareholders to buy the support at 60 cents and 50 cents and 40 cents? Will you feel responsible at all if shareholders lose everything here?
Stock is about to reach the value menu level of 4 for a dollar, I'm sure you're proud smh.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
